A COMPARITIVE STUDY OF TOPICAL MINOXIDIL (5%) PLUS FINASTERIDE (0.1%) VERSUS PLATELET-RICH PLASMA PLUS TOPICAL MINOXIDIL (5%) PLUS FINASTERIDE (0.1%) IN PATIENTS WITH ANDROGENIC ALOPECIA

DHARA D PATEL; SOM J LAKHANI; SPANDAN K SHAH; KRUNAL TRALSAWALA; ARTI K BHABHOR

doi:10.22159/ajpcr.2024v17i12.51859

Authors

DHARA D PATEL Department of Dermatology, Parul Institute of Medical Sciences and Research, Parul University, Vadodara, Gujarat, India. https://orcid.org/0009-0009-5273-8887
SOM J LAKHANI Department of Dermatology, Parul Institute of Medical Sciences and Research, Parul University, Vadodara, Gujarat, India.
SPANDAN K SHAH Department of Dermatology, Parul Institute of Medical Sciences and Research, Parul University, Vadodara, Gujarat, India.
KRUNAL TRALSAWALA Department of Dermatology, Parul Institute of Medical Sciences and Research, Parul University, Vadodara, Gujarat, India.
ARTI K BHABHOR Department of Dermatology, Parul Institute of Medical Sciences and Research, Parul University, Vadodara, Gujarat, India.

DOI:

https://doi.org/10.22159/ajpcr.2024v17i12.51859

Keywords:

Platelet rich plasma, Androgenic alopecia, Minoxidil, Finasteride, Subjective response

Abstract

Objective: Androgenic alopecia is progressive loss of terminal hairs in patterned distribution. It causes psychoemotional problems and affects the quality of life. Therefore, to achieve optimal results, multiple modalities are required. In this study, the combination of platelet-rich plasma (PRP) along with topical drugs such as minoxidil and finasteride is compared with the conventional combination of topical minoxidil (5%)+Finasteride (0.1%)

Methods: A prospective randomized study was conducted on a total of 50 males with androgenetic alopecia (AGA) at the Department of Dermatology, Parul Institute of Medical Sciences and Research for 1 year. A total of 50 males diagnosed with AGA were divided into two groups randomly. Patients in in Group A were recommended topical minoxidil (5%)+finasteride (0.1%), and Group B was treated with PRP along with topical minoxidil (5%)+finasteride (0.1%). PRP was done every month for 6 months and minoxidil applied over scalp twice daily for 6 months. Both groups were followed up monthly for 6 months and then after 6 months of last visit. Hair density was assessed using the Hamilton–Norwood scale using photographs and patient’s self-assessment scores. Data were evaluated applying Chi-square test.

Results: After 6 months of the last visit subjective response with minoxidil (5%) +finasteride (0.1%) showed good response in 26%, moderate in 39%, and poor in 35%, whereas PRP+minoxidil (5%)+finasteride (0.1%) group showed good response in 65%, 26% responded moderately and 9% responded poorly.

Conclusion: The combination therapy of PRP and topical minoxidil+finasteride being safe and effective can be used for patients unresponsive to conventional therapy and for faster outcome.

Downloads

Download data is not yet available.

References

Mella JM, Perret MC, Manzotti M, Catalano HN, Guyatt G. Efficacy and safety of finasteride therapy for androgenetic alopecia: A systematic review. Arch Dermatol. 2010 Oct;146(10):1141-50. doi: 10.1001/ archdermatol.2010.256, PMID: 20956649

Yepuri V, Venkataram M. Platelet-rich plasma with microneedling in androgenetic alopecia: Study of efficacy of the treatment and the number of sessions required. J Cutan Aesthet Surg. 2021 Apr- Jun;14(2):184-90. doi: 10.4103/JCAS.JCAS_33_20, PMID: 34566361, PMCID: PMC8423195

Dhurat R, Sukesh M, Avhad G, Dandale A, Pal A, Pund P. A randomized evaluator blinded study of effect of microneedling in androgenetic alopecia: A pilot study. Int J Trichology. 2013 Jan;5(1):6-11. doi: 10.4103/0974-7753.114700, PMID: 23960389, PMCID: PMC3746236

Blumeyer A, Tosti A, Messenger A, Reygagne P, Del Marmol V, Spuls PI, et al. Evidence-based (S3) guideline for the treatment of androgenetic alopecia in women and in men. J Dtsch Dermatol Ges. 2011 Oct;9(Suppl 6):S1-57. doi: 10.1111/j.1610-0379.2011.07802.x, PMID: 21980982

Hillmann K, Blume-Peytavi U. Diagnosis of hair disorders. Semin Cutan Med Surg. 2009 Mar;28(1):33-8. doi: 10.1016/j.sder.2008.12.005, PMID: 19341940

Gupta AK, Carviel JL. Meta-analysis of efficacy of platelet-rich plasma therapy for androgenetic alopecia. J Dermatolog Treat. 2017 Feb;28(1):55-8. doi: 10.1080/09546634.2016.1179712, PMID: 27152474

Gkini MA, Kouskoukis AE, Tripsianis G, Rigopoulos D, Kouskoukis K. Study of platelet-rich plasma injections in the treatment of androgenetic alopecia through an one-year period. J Cutan Aesthet Surg. 2014 Oct-Dec;7(4):213-9. doi: 10.4103/0974-2077.150743, PMID: 25722600, PMCID: PMC4338465

Maria-Angeliki G, Alexandros-Efstratios K, Dimitris R, Konstantinos K. Platelet-rich plasma as a potential treatment for noncicatricial alopecias. Int J Trichology. 2015 Apr-Jun;7(2):54-63. doi: 10.4103/0974-7753.160098, PMID: 26180449, PMCID: PMC4502475

Gentile P, Garcovich S, Bielli A, Scioli MG, Orlandi A, Cervelli V. The effect of platelet-rich plasma in hair regrowth: A randomized placebo-controlled trial. Stem Cells Transl Med. 2015 Nov;4(11):1317-23. doi: 10.5966/sctm.2015-0107, PMID: 26400925, PMCID: PMC4622412

Krupa Shankar D, Chakravarthi M, Shilpakar R. Male androgenetic alopecia: Population-based study in 1,005 subjects. Int J Trichology. 2009 Jul;1(2):131-3. doi: 10.4103/0974-7753.58556, PMID: 20927235, PMCID: PMC2938575